Nothing Special   »   [go: up one dir, main page]

CN115894340B - Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof - Google Patents

Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof Download PDF

Info

Publication number
CN115894340B
CN115894340B CN202211281061.0A CN202211281061A CN115894340B CN 115894340 B CN115894340 B CN 115894340B CN 202211281061 A CN202211281061 A CN 202211281061A CN 115894340 B CN115894340 B CN 115894340B
Authority
CN
China
Prior art keywords
bupivacaine
meloxicam
single crystal
meloxicam salt
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211281061.0A
Other languages
Chinese (zh)
Other versions
CN115894340A (en
Inventor
唐田
陈柏州
梁东丽
孙彦辉
林锐彬
蒋娟娟
刘淑芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiali Shenzhen Biotechnology Co ltd
Original Assignee
Jiali Shenzhen Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiali Shenzhen Biotechnology Co ltd filed Critical Jiali Shenzhen Biotechnology Co ltd
Priority to CN202211281061.0A priority Critical patent/CN115894340B/en
Publication of CN115894340A publication Critical patent/CN115894340A/en
Priority to PCT/CN2023/120714 priority patent/WO2024082917A1/en
Application granted granted Critical
Publication of CN115894340B publication Critical patent/CN115894340B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The application relates to a crystal form A of bupivacaine meloxicam salt and a single crystal, a preparation method and application thereof. The crystalline form a of bupivacaine meloxicam salt having an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ (°) angles: 7.5.+ -. 0.2, 8.3.+ -. 0.2, 12.7.+ -. 0.2, 15.1.+ -. 0.2, 16.1.+ -. 0.2, 16.6.+ -. 0.2, 24.9.+ -. 0.2 and 25.0.+ -. 0.2. The A crystal form has stable form and definite melting point, good chemical stability, high temperature resistance and high illumination, has the performance required by preparing a solid preparation, and has the advantages of higher drug administration concentration, better dissolution, better compressibility and disintegration, convenient storage, simpler production operation of the preparation and easier quality control.

Description

Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof
Technical Field
The application relates to the technical field of medicines, in particular to a crystal form A of bupivacaine meloxicam salt, a single crystal thereof, a preparation method and application.
Background
Bupivacaine (Bupivacaine) is an amide local anesthetic, the first product on the market is bupivacaine hydrochloride injection, developed and marketed by Hospira in 1972 for use in surgical, oral, diagnostic and therapeutic operations and obstetric operations, under the trade name Marcaine, and bupivacaine has therefore also been called bupivacaine. As a non-opioid, bupivacaine avoids the addictive nature of opioids, but the conventional dosing concentration of bupivacaine is 0.5%. Thus, there is an urgent need to increase the concentration of drug administered in clinic, and there is an urgent need to solve the solubility of drugs in pharmacy.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) and antipyretic, currently used to alleviate the symptoms of arthritis, fever, and as an analgesic for inflammatory conditions. Meloxicam was originally developed by BoehringerIngelheim and marketed in europe under the brands Melox, movalis and Recoxa for the treatment of rheumatoid arthritis, for short term use in osteoarthritis and ankylosing spondylitis. Meloxicam is commercialized as tablets, orally disintegrating tablets and capsules, 7.5 and 15 mg per dose, and 7.5 mg per 5 ml per dose of oral suspension.
The bupivacaine/meloxicam sustained-release liquid (trade name: zynrelef, development code: HTX-011) was developed by HeronTherapeutics company, was approved by FDA for marketing on day 13, 05, 2021, and was instilled around soft tissues or joints in the operation area after bunyaosteotomy, open inguinal hernia repair, and total knee replacement in adult patients, resulting in postoperative analgesia. The product is approved by European Union as early as 09 in 2020, and can be used for treating somatic postoperative pain caused by small and medium-sized surgical wounds in adults.
Zynrelef is a fixed dose combination of bupivacaine and meloxicam in a ratio of 33:1.1, wherein the lower amount of meloxicam as a non-steroidal anti-inflammatory drug (NSAID) reduces wound inflammation, relieves pain, increases the local pH of the wound, brings the pH to normal and allows more bupivacaine to penetrate the cell membrane, thereby achieving good synergistic analgesic effect.
Zynrelef is currently the only commercially available double-acting local anesthetic (Dual-actingLocal Anesthetic, DALA), but the preparation adoptsThe technology takes fourth generation polyorthoester (Polyorthoesters, POE) prepared by condensation of glycol and diketone acetal as a material, and the polyorthoester material is actually a composite material and comprises diethylene tetraoxaspiro undecane, triethylene glycol and triethylene glycol polyglycolide. The pharmaceutical stability of these novel adjuvants is to be examined and the use of DMSO as a formulation solvent is required, and further confirmation of the application in the art is also to be made.
Disclosure of Invention
Based on the above, the application provides a crystal form A of bupivacaine meloxicam salt with higher administration concentration, better dissolution and stable property, and a single crystal, a preparation method and application thereof.
In a first aspect of the present invention, there is provided a crystalline form a of bupivacaine meloxicam salt having an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ (°) angles:
7.5±0.2、8.3±0.2、12.7±0.2、15.1±0.2、16.1±0.2、16.6±0.2、24.9±0.2、25.0±0.2。
2. Form a of bupivacaine meloxicam salt according to claim 1, further comprising 1 or 2 or more characteristic diffraction peaks at 2Θ (°) angles selected from: 18.9.+ -. 0.2, 10.1.+ -. 0.2, 17.3.+ -. 0.2, 18.9.+ -. 0.2, 21.0.+ -. 0.2, 25.2.+ -. 0.2.
According to a second aspect of the present invention, there is provided a process for the preparation of form a of bupivacaine meloxicam salt according to the first aspect, comprising the steps of:
Mixing bupivacaine, meloxicam and an organic solvent, heating and refluxing until the bupivacaine, meloxicam and the organic solvent are dissolved, concentrating the reaction solution until solid is separated out, adding an anti-solvent, continuously separating out the solid, collecting the solid, and drying to prepare the A crystal form of the bupivacaine meloxicam salt.
In a third aspect of the present invention, there is provided a single crystal of form a of the salt of bupivacaine of the first aspect, comprising 4 single crystal molecules of the salt of bupivacaine in a unit cell structure.
In a fourth aspect of the present invention, there is provided a pharmaceutical composition comprising one or more of the crystalline form a of bupivacaine meloxicam salt according to the first aspect and the single crystal of crystalline form a of bupivacaine meloxicam salt according to the third aspect, together with a pharmaceutically acceptable carrier and/or excipient.
According to a fifth aspect of the present invention, there is provided the use of the crystalline form a of bupivacaine meloxicam salt according to the first aspect, the single crystal of the crystalline form a of bupivacaine meloxicam salt according to the third aspect, or the pharmaceutical composition according to the fourth aspect for the manufacture of a medicament for the treatment of localized pain.
In the process of preparing the crystalline compound of the bupivacaine meloxicam salt, the inventor crystallizes the crude product of the substance by a recrystallization method to obtain a new crystal form, namely a crystal form A. The obtained crystals were confirmed to be a novel crystal, namely, form a of a crystalline compound of 1-N-butyl-2- (2, 6-dimethylcarbamoyl) piperidine and 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboxamide 1, 1-dioxide, by subjecting the crystals to detection and analysis such as X-ray powder diffraction, DSC, TG, IR, elemental analysis, etc. The A crystal form has stable form and definite melting point, good chemical stability, high temperature resistance and high illumination, has the performance required by preparing a solid preparation, and has the advantages of higher drug administration concentration, better dissolution, better compressibility and disintegration, convenient storage, simpler production operation of the preparation and easier quality control.
Meanwhile, the A crystal form also has good bioavailability in the research process.
Drawings
FIG. 1 is an X-ray diffraction pattern of form A obtained in example 1 of the present invention;
FIG. 2 is a DSC chart of form A obtained in example 1 of the present invention;
FIG. 3 is a pattern of TG in form A obtained in example 1 of the present invention;
FIG. 4 is an IR spectrum of form A obtained in example 1 of the present invention;
FIG. 5 is an HPLC chart of form A obtained in example 1 of the present invention;
FIG. 6 is a comparative graph of the stability test of form A obtained in example 1 of the present invention;
FIG. 7 is a graph comparing the bioavailability of bupivacaine in animals of form A obtained in example 1 of the present invention;
FIG. 8 is a crystal morphology of a single crystal obtained in example 20 of the present invention;
FIG. 9 is a molecular structure and atomic number (club diagram) of a single crystal obtained in example 20 of the present invention;
FIG. 10 is a molecular structure and atomic number (line pattern) of a single crystal obtained in example 20 of the present invention;
FIG. 11 is a unit cell structure (in atomic scale) of the single crystal obtained in example 20 of the present invention;
FIG. 12 is a unit cell structure (in symmetry) of the single crystal obtained in example 20 of the present invention;
FIG. 13 is an absolute configuration of a single crystal (wherein black C is a chiral C atom) obtained in example 20 of the present invention.
Detailed Description
The form a of bupivacaine meloxicam salt and its single crystals, preparation method and application according to the present application are described in further detail below with reference to specific examples. The present application may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein in the description of the application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.
Herein, "one or more" refers to any one, any two, or any two or more of the listed items.
In the present application, "first aspect", "second aspect", "third aspect", "fourth aspect", etc. are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or quantity, nor as implying an importance or quantity of technical features indicated. Moreover, the terms "first," "second," "third," "fourth," and the like are used for non-exhaustive list description purposes only, and are not to be construed as limiting the number of closed forms.
In the application, the technical characteristics described in an open mode comprise a closed technical scheme composed of the listed characteristics and also comprise an open technical scheme comprising the listed characteristics.
In the present application, the numerical ranges are referred to as continuous, and include the minimum and maximum values of the ranges, and each value between the minimum and maximum values, unless otherwise specified. Further, when a range refers to an integer, each integer between the minimum and maximum values of the range is included. Further, when multiple range description features or characteristics are provided, the ranges may be combined. In other words, unless otherwise indicated, all ranges disclosed herein are to be understood to include any and all subranges subsumed therein.
The percentage content referred to in the present application refers to mass percentage for both solid-liquid mixing and solid-solid mixing and volume percentage for liquid-liquid mixing unless otherwise specified.
The percentage concentrations referred to in the present application refer to the final concentrations unless otherwise specified. The final concentration refers to the ratio of the additive component in the system after the component is added.
The temperature parameter in the present application is not particularly limited, and may be a constant temperature treatment or a treatment within a predetermined temperature range. The constant temperature process allows the temperature to fluctuate within the accuracy of the instrument control.
Room temperature in the present application generally means 4 ℃ to 30 ℃, preferably 22 ℃ to 27 ℃.
The application relates to a salt of bupivacaine meloxicam, which is generated by the reaction of bupivacaine and meloxicam and has the following structural characteristics:
the chemical name of the bupivacaine meloxicam salt is 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboxamide 1, 1-dioxide and 1-N-butyl-2- (2, 6-dimethylcarbamoyl) piperidine.
The application provides a crystal form A of bupivacaine meloxicam salt, which has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2 theta (DEG) angles:
7.5.+ -. 0.2, 8.3.+ -. 0.2, 12.7.+ -. 0.2, 15.1.+ -. 0.2, 16.1.+ -. 0.2, 16.6.+ -. 0.2, 24.9.+ -. 0.2 and 25.0.+ -. 0.2.
The radiation source used in the X-ray powder diffraction pattern is, without limitation, cu radiation source. The X-ray powder diffraction pattern refers to a PXRD pattern.
Further, the X-ray powder diffraction pattern of form a has characteristic diffraction peaks at the following 2θ (°) angles:
7.5.+ -. 0.1, 8.3.+ -. 0.1, 12.7.+ -. 0.1, 15.1.+ -. 0.1, 16.1.+ -. 0.1, 16.6.+ -. 0.1, 24.9.+ -. 0.1 and 25.0.+ -. 0.1.
Further, the relative intensities (I/I 0) of the characteristic diffraction peaks are all greater than or equal to 30%.
In one example, the form a further comprises 1 or 2 or more characteristic diffraction peaks at 2θ (°) angles selected from: 18.9.+ -. 0.2, 10.1.+ -. 0.2, 17.3.+ -. 0.2, 18.9.+ -. 0.2, 21.0.+ -. 0.2 and 25.2.+ -. 0.2.
The radiation source used in the X-ray powder diffraction pattern is, without limitation, cu radiation source. The X-ray powder diffraction pattern refers to a PXRD pattern.
Further, the form a further comprises 1 or 2 or more characteristic diffraction peaks at 2θ (°) angles selected from: 18.9.+ -. 0.1, 10.1.+ -. 0.1, 17.3.+ -. 0.1, 18.9.+ -. 0.1, 21.0.+ -. 0.1 and 25.2.+ -. 0.1.
Further, the relative intensities (I/I 0) of the characteristic diffraction peaks are all 20% or more.
In one example, the form a further comprises 1 or 2 or more characteristic diffraction peaks at 2θ (°) angles selected from: 18.1.+ -. 0.2, 20.2.+ -. 0.2, 22.7.+ -. 0.2, 23.8.+ -. 0.2, 24.0.+ -. 0.2, 25.8.+ -. 0.2, 26.4.+ -. 0.2 and 26.5.+ -. 0.2.
The radiation source used in the X-ray powder diffraction pattern is, without limitation, cu radiation source. The X-ray powder diffraction pattern refers to a PXRD pattern.
Further, the form a further comprises 1 or 2 or more characteristic diffraction peaks at 2θ (°) angles selected from: 18.1.+ -. 0.1, 20.2.+ -. 0.1, 22.7.+ -. 0.1, 23.8.+ -. 0.1, 24.0.+ -. 0.1, 25.8.+ -. 0.1, 26.4.+ -. 0.1 and 26.5.+ -. 0.1.
Further, the relative intensities (I/I 0) of the characteristic diffraction peaks are all 10% or more.
In one example, the main parameters of the X-ray powder diffraction pattern of form a of the form a are as follows:
where the relative intensity values are close values, "close" refers to the uncertainty of the intensity measurement, and one skilled in the art understands that the uncertainty of the relative intensity is related to the measurement conditions and may vary, for example, within a range of + -25% or preferably within a range of + -10%.
In one example, the form a has an X-ray powder diffraction pattern substantially as shown in figure 1. The radiation source used in the X-ray powder diffraction pattern is, without limitation, cu radiation source. The X-ray powder diffraction pattern refers to a PXRD pattern.
In one example, the differential scanning calorimetry curve of form a has an endothermic peak at 189.6 ℃ ± 3 ℃. Further, the differential scanning calorimetry curve of the form a has an endothermic peak at 189.6 ℃ ± 1 ℃.
In one example, the differential scanning calorimetric curve of form a is substantially as shown in fig. 2.
In one example, the thermogram of form a has a 57% ± 1% weight loss in the range of 210 ℃ to 300 ℃.
In one example, the thermogram of form a is substantially as shown in fig. 3. Meanwhile, thermogravimetric spectra (TGA) showed a weight loss of 0.4% ± 1% in the range of 50 ℃ to 150 ℃, which is a loss caused by solvent residue.
In one example, the infrared spectrum of form a includes the following absorption peaks:
3436cm-1、3291cm-1、2960cm-1、1690cm-1、1603cm-1、1549cm-1、1522cm-1、1456cm-1、1395cm-1、1337cm-1、1233cm-1、1188cm-1、1169cm-1、1125cm-1、1067cm-1、941cm-1、861cm-1、768cm-1、741cm-1、619cm-1、574cm-1、524cm-1 And 464cm -1.
In one example, the infrared spectrum of form a is substantially as shown in fig. 4.
The application also provides a preparation method of the A crystal form of the bupivacaine meloxicam salt, which comprises the following steps:
Mixing bupivacaine, meloxicam and an organic solvent, heating and refluxing until the bupivacaine, meloxicam and the organic solvent are dissolved, concentrating the reaction solution until solid is separated out, adding an anti-solvent, continuously separating out the solid, collecting the solid, and drying to prepare the A crystal form of the bupivacaine meloxicam salt.
In one example, the organic solvent is one or more of butanone, acetone, tetrahydrofuran, acetonitrile, dimethyl sulfoxide, ethyl acetate, and isopropyl acetate; further, the organic solvent is acetone.
In one example, the anti-solvent is one or more of water, isopropanol, and n-heptane. Further, the antisolvent is water.
In one example, the volume ratio of the organic solvent to the antisolvent is 1-4:1. Further, the volume ratio of the organic solvent to the antisolvent is 1.5-2.5:1.
In one example, the molar ratio of meloxicam to bupivacaine is 1:1 to 5. Further, the molar ratio of meloxicam to bupivacaine is 1:1-2.
In one example, the ratio between the total mass of bupivacaine and meloxicam and the total volume of the organic solvent and antisolvent is from 5mg to 20mg to 1ml. Further, the ratio is 7mg to 11mg to 1mL.
In one example, the temperature of the heated reflux is 30 ℃ to 80 ℃. Further, the temperature of the heating reflux is 58-62 ℃.
In one example, the time to continue to precipitate solids is 2 to 8 hours. Further, the time for continuing to precipitate the solid is 3 to 5 hours.
In one example, the temperature at which solids continue to precipitate is 0 to 40 ℃. Further, the temperature at which the solid is continuously precipitated is 20 to 30 ℃.
In one example, the temperature of drying is 30 ℃ to 60 ℃. Further, the drying temperature is 45-55 ℃.
In one example, the temperature of concentration is 40℃to 50℃and the pressure is-0.2 MPa to-0.1 MPa.
The application also provides a single crystal of form a of the salt of bupivacaine as described above, having a unit cell structure in which one unit cell comprises 4 single crystal molecules of the salt of bupivacaine.
In one example, in the single crystal unit cell structure, the independent symmetry elements are double helical axes and n slip planes.
In one example, the crystallographic structural parameters of the single crystal are as follows:
The application also provides a preparation method of the single crystal of the A crystal form of the bupivacaine meloxicam salt, which comprises the following steps:
Mixing bupivacaine, meloxicam and an organic solvent, heating and refluxing until the bupivacaine, meloxicam and the organic solvent are dissolved, volatilizing the organic solvent in the reaction liquid until solids are separated out, and collecting the solids to prepare the single crystal.
In one example, the organic solvent is one or more of butanone, acetone, tetrahydrofuran, acetonitrile, dimethyl sulfoxide, ethyl acetate, and isopropyl acetate. Further, the organic solvent is acetone.
In one example, the molar ratio of meloxicam to bupivacaine is 1:1 to 5. Further, the molar ratio of meloxicam to bupivacaine is 1:1-2.
In one example, the ratio between the total mass of bupivacaine and meloxicam and the volume of the organic solvent is 5mg to 20mg to 1ml. Further, the ratio is 7mg to 11mg to 1mL.
In one example, the temperature of the heated reflux is 30 ℃ to 80 ℃; further, the temperature of the heating reflux is 58-62 ℃.
In one example, volatilizing the organic solvent in the reaction solution includes the steps of: and placing the reaction liquid in a glass bottle, sealing the reaction liquid by a sealing layer, and arranging a vent hole on the sealing layer. The sealing layer is, without limitation, a sealing film.
Further, the vent holes are 1-2 holes pricked by the needle of a 10mL syringe.
In one example, the organic solvent in the reaction solution is volatilized for 2 to 10 days at room temperature.
The application also provides a pharmaceutical composition comprising one or more of the crystal form a of the bupivacaine meloxicam salt as described above and the single crystal form a of the bupivacaine meloxicam salt as described above, and a pharmaceutically acceptable carrier and/or excipient.
It will be appreciated that the above pharmaceutical compositions may be further formulated in a form for administration, including oral or parenteral administration, according to conventional formulation methods. In a pharmaceutically acceptable form, a therapeutically effective amount of the crystalline form a of bupivacaine meloxicam salt and/or a single crystal of the crystalline form a of bupivacaine meloxicam salt should be included. By "therapeutically effective amount" is meant that at this dose, the crystalline form a of bupivacaine meloxicam salt and the single crystals of the crystalline form a of bupivacaine meloxicam salt according to the invention not only have improved therapeutic activity for pain relief, but also exhibit greatly improved solubility when used for parenteral administration and greatly improved transdermal permeability when used for topical treatment.
Without limitation, the pharmaceutical composition is suitable for use in topical treatment in a formulation format including, but not limited to, solutions, gels, milk gels, creams, ointments, lotions, skin patches or eye drops. The pharmaceutical composition is also suitable for parenteral injection.
The application also provides application of the pharmaceutical composition in preparation of medicines with effects of treating local pain. Such localized pain includes, but is not limited to, muscle pain, joint pain, pain associated with herpes infections, wound pain (such as surgical pain or burn pain), and the like.
The pharmaceutical composition of the application is particularly suitable for use in the treatment of patients with localized pain. Without limitation, it is by topical and parenteral treatment of these patients with an effective amount of the pharmaceutical formulation.
The following are specific examples.
Meloxicam, bupivacaine and other agents referred to in the examples are all commercially available.
Test conditions for example samples:
PXRD (first):
detection instrument: rigaku SmartLab SE A
Detection conditions: the voltage of the X-ray tube is 40kV, the current of the X-ray tube is 40mA, the scanning range is 3-40 degrees (2 theta), the step size is 0.02 degrees, and the scanning speed is 5 degrees/min.
The detection basis is as follows: account IX FX ray powder diffraction method of the people's republic of China (second edition 2020)
Detection result: as in fig. 1.
(II) DSC
Detection instrument: relaxation-resistant STA449F3
Detection conditions: nitrogen, 50mL/min
Scanning procedure: 30-350 ℃, and the temperature rising rate is as follows: 10 ℃/min
Detecting the mass of a sample: 2.906mg (alumina sample tray)
The detection basis is as follows: JY/T014-1996 thermal analysis method general rule
Detection result: as in fig. 2.
(III) TGA
Detection instrument: relaxation-resistant STA 449F3
Detection conditions: nitrogen, 50mL/min
Scanning procedure: 30-350 ℃, and the temperature rising rate is as follows: 10 ℃/min
Detecting the mass of a sample: 1.68mg (alumina sample tray)
The detection basis is as follows: JY/T014-1996 thermal analysis method general rule
Detection result: as in fig. 3.
(IV) Infrared Spectrum
Detection instrument: PE Fourier transform infrared microscope system (Spotlight 200 i)
Detection conditions: potassium bromide tabletting method
The detection basis is as follows: GB/T6040-2002 infrared spectrum analysis method general rule
Detection result: as in fig. 4.
(V) HPLC
Detection instrument: WATERS ALLIANCE E2695,995
Chromatographic column: reverse C18 liquid chromatographic column (octadecylsilane chemically bonded silica is used as filler)
Column temperature: 30 DEG C
Mobile phase: methanol-0.1 mol/L ammonium acetate solution (1:1)
Detection wavelength: 270nm
Detection result: as in fig. 5.
(Six) SXRD
Detection instrument: bruker D8 VENTURE double micro focal spot single crystal X-ray diffractometer
Detection conditions: ambient temperature 193K, enhanced Cu light source, wavelength
The detection basis is as follows: JY/T0588-2020 general rules of analysis methods for measuring crystals and molecular structures of small molecular compounds by single crystal X-ray diffractometer
Detection result: as shown in fig. 8-13.
Preparation of crystalline compound A of 1-N-butyl-2- (2, 6-dimethylcarbamoyl) piperidine and 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboxamide 1, 1-dioxide
Example 1 preparation of crystalline form a of bupivacaine/meloxicam salt by means of a solution crystallization process.
10G of meloxicam and 8.2g of bupivacaine were added to 2L of acetone (organic solvent), heated to reflux at 60℃and stirred to dissolve completely. Concentrating the clear solution under reduced pressure (45 ℃ and minus 0.1 MPa) until solid is precipitated, stopping concentrating, adding 1L of n-heptane (anti-solvent) and stirring at 25 ℃ (solid precipitation temperature) for 4 hours (solid precipitation time), filtering, and vacuum drying the solid sample at 50 ℃ (drying temperature) for 12 hours to obtain the bupivacaine meloxicam salt A crystal form. 15.8g of pale yellow solid powder, and the mass yield is 86.5%.
The identification of the compound properties is shown in FIGS. 1 to 5.
Examples 2 to 16
10G of meloxicam and 8.2g of bupivacaine were added to the reaction flask, and the experiment was carried out in the same manner as in example 1, while changing the parameters as shown in Table 1 below:
TABLE 1
Example 17
The stability of the crystalline form a of bupivacaine meloxicam salt of example 1 was examined under conditions of high temperature (50 ℃) and light and acceleration (40 ℃,75% rh), and samples were taken for 5 days and 10 days, respectively, and PXRD and HPLC measurements were performed, and the results are shown in table 2 and fig. 6. The results show that the bupivacaine meloxicam salt A crystal form is stable when the water content, the purity and the crystal form are compared with the data of 0 day under the conditions of high temperature, illumination and acceleration.
Table 2 results of the stability test of bupivacaine/meloxicam salt form a
EXAMPLE 18 preparation of solid pharmaceutical preparation
Prescription 1:
Composition of the components Dosage of
Crystal form A of bupivacaine meloxicam salt (example 1) 10mg
Mannitol (mannitol) 108mg
Lactose and lactose 50mg
Crosslinked povidone 6mg
Micro powder silica gel 3mg
Glyceryl behenate 3mg
Total amount of 180mg
The preparation method comprises the following steps: the above components are mixed according to a conventional preparation method and directly compressed into tablets.
Prescription 2:
Composition of the components Dosage of
Crystal form A of bupivacaine meloxicam salt (example 1) 10g
Mannitol (mannitol) 80g
Lactose and lactose 65g
Crosslinked povidone 15g
Micro powder silica gel 5g
Glyceryl behenate 5g
3％HPMC Proper amount of
Total amount of 180g
The preparation method comprises the following steps: uniformly mixing the bupivacaine meloxicam salt A crystal form of the example 1 with mannitol, lactose and crospovidone according to an equivalent multiplication method, adding a pre-prepared HPMC solution to prepare a soft material, granulating by a 20-mesh sieve, drying at 60 ℃ for 30 minutes, sieving by a 18-mesh sieve, granulating, adding aerosil, and filling into a No. 2 capsule.
Control formula:
the preparation method comprises the following steps: the above components are mixed according to a conventional preparation method and directly compressed into tablets.
Example 19 influence factor control test
According to the preparation method, 3 batches of samples are prepared according to the processes of prescriptions 1-2 and comparative prescriptions in the embodiment 18, after basic project inspection is qualified, illumination, high temperature and high humidity tests are respectively carried out, and the appearance property, content and dissolution of the samples are inspected, so that the results of influence factors show that the samples are stable in properties under the conditions of high temperature and illumination, and can be used as reference prescriptions and processes of preparations.
The dissolution rate, the compressibility and the disintegration of the prescriptions 1-2 and the comparison prescriptions are tested, and the dissolution rate testing method is a first method or a second method of < dissolution rate and release rate measuring method 0931> in the fourth part of the Chinese pharmacopoeia 2020 edition; the disintegration test method is < disintegration time limit check method 0921> in the fourth part of China pharmacopoeia 2020 edition; the compressibility is generally determined by whether or not the appearance of the tablet is cracked, covered, or hard.
The test results are shown in table 3 below:
TABLE 3 Table 3
Investigation index Prescription 1 Prescription 2 Contrast prescription
Dissolution rate Good (good) Good (good) Difference of difference
Compressibility of Good (good) / Preferably, it is
Degree of disintegration Good (good) Preferably, it is Difference of difference
According to the dissolution test of 2020 edition pharmacopoeia, the dissolution rate of the prescription 1-2 in 15 minutes is over 80 percent. The dissolution rate of the comparative prescription is only 70% in 15 minutes, and meanwhile, the compressibility and the disintegration rate are better than those of the comparative prescription.
Meanwhile, the crystalline form A of bupivacaine meloxicam salt has a melting point of 189.6 ℃ and bupivacaine has a melting point of 106 to 110 ℃, and the solubility of bupivacaine meloxicam salt A and bupivacaine melongene has the following difference in table 4:
TABLE 4 Table 4
Solvent(s) Bupivacaine solubility Solubility of bupivacaine/meloxicam salt form A
H2O <1mg/ml >1.5mg/ml
EtOH <1mg/ml >1.5mg/ml
MeOH <1mg/ml >1.7mg/ml
IPA <1mg/ml <1mg/ml
Acetone >1.6mg/ml >4.0mg/ml
ACN <1mg/ml >1.7mg/ml
MTBE <1mg/ml <1mg/ml
1，4-Dioxane >1.6mg/ml >1.1mg/ml
DMF >35mg/ml >100mg/ml
EA <1mg/ml <1mg/ml
DMSO >52mg/ml >100mg/ml
DMA >52mg/ml >100mg/ml
NMP >51mg/ml >100mg/ml
Toluene <1mg/ml <1mg/ml
Therefore, compared with a single product of bupivacaine, the crystal form A of the bupivacaine meloxicam salt disclosed by the application has the advantages of better investigation indexes such as dissolution rate, compressibility, disintegration and the like of the preparation, and differences in the aspects of melting point, solubility, crystal solubility and the like.
EXAMPLE 20 bioavailability assay
The bupivacaine and bupivacaine meloxicam salt A crystal form and bupivacaine of example 1 are respectively administered by intragastric administration to rats at a dose of 1.5 mg/kg; each group of animals was plasma taken at different time points (0, 0.0833, 0.25, 0.5, 1,2,3, 4, 6, 8, 12, 24, 30, 48 hours) and blood concentrations were measured at the different time points.
The test results are shown in table 5 and fig. 7 below:
TABLE 5
The results show that the bioavailability of the bupivacaine meloxicam salt A crystal form in animal bodies is obviously improved, and the AUC of the bupivacaine meloxicam salt A crystal form is about 10 times that of bupivacaine, thus having quite obvious pharmacokinetic behavior improvement effect.
EXAMPLE 21 Bubicaine/meloxicam salt single crystal culture
20Mg of meloxicam and 16.4mg of bupivacaine are added into 4mL of acetone, the mixture is heated to 60 ℃ to be completely dissolved, the clear solution is placed into a glass bottle, and the mixture is subjected to hole punching and volatilization for 48 hours at 25 ℃ to obtain single crystals of the meloxicam salt A crystal form of the bupivacaine, which are light yellow rod-shaped crystals, and the crystal morphology is shown in figure 8.
The obtained single crystal is subjected to X-ray single crystal diffraction analysis to obtain a crystallographic data table and a structural diagram
The basic structure is as follows:
the molecular structure in the unit cell of the single crystal of bupivacaine meloxicam salt is presented for fig. 9 and 10, where each atom number in the molecule is identified and hydrogen is not numbered for clarity. For ease of description, the present application refers to each atom by atomic number in the figures.
Unit cell structure:
The crystal cell structure is presented for fig. 11 and 12, with 4 single crystal molecules of bupivacaine/meloxicam salt in one cell. The independent symmetrical elements in the crystal are double helical axes and n slip planes.
Absolute configuration
The absolute configuration represents the real arrangement relation of each group in the chiral molecule in space, namely the absolute spatial relation. Figure 13 shows the absolute configuration of the single crystal molecules of bupivacaine meloxicam salt within the unit cell, each single crystal molecule of bupivacaine meloxicam salt comprising 1 chiral carbon atom (black label) with an absolute configuration of C24 (R).
Specifically, the crystal data of the bupivacaine meloxicam salt single crystal are shown in tables 6 to 13:
TABLE 6 crystallographic structural parameters
TABLE 7 atomic coordinates (. Times.10 4) and equivalent isotropic Displacement parameters
TABLE 8 bond length and bond angle of bonded atoms
TABLE 9 bond angles and bond lengths of bonded atoms
TABLE 10 Anisotropic displacement factor index
Note that: form of anisotropic displacement factor index: -2pi [ h 2 a*2U11+...+2h k a*b*U 12 ], wherein a, b, c are unit lengths of the reciprocal lattice; u 11、U22、U33、U23、U13 and U 12 are anisotropic displacement parameters, which are also called temperature factors; h. k and l are diffraction indexes; parallel X-rays are directed to a perfectly sized single crystal, and diffraction occurs when the optical path difference satisfies an integer multiple of the conditional wavelength.
According to the three-dimensional laue equation:
a(cosα0-cosα)＝hλ
b(cosβ0-cosβ)＝kλ
c(cosγ0-cosγ)＝lλ
h. k and l are integers, and a group of h, k and l are called diffraction indexes, which define a specific diffraction direction.
TABLE 11 Hydrogen atom coordinates (. Times.10 4) and equivalent isotropic Displacement parameters
Table 12 Single crystal torsion angle (°)
TABLE 13 Hydrogen bonding
The technical features of the above-described embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above-described embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The above examples merely illustrate a few embodiments of the present application, which are convenient for a specific and detailed understanding of the technical solutions of the present application, but should not be construed as limiting the scope of the claims. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the application, which are all within the scope of the application. It should be understood that, based on the technical solutions provided by the present application, those skilled in the art may obtain technical solutions through logical analysis, reasoning or limited experiments, which are all within the scope of protection of the appended claims. The scope of the patent is therefore intended to be covered by the appended claims, and the description and drawings may be interpreted as illustrative of the contents of the claims.

Claims (12)

1. A crystalline form a of bupivacaine meloxicam salt having an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ (°) angles:
7.5±0.2、8.3±0.2、10.1±0.2、12.7±0.2、15.1±0.2、16.1±0.2、16.6±0.2、17.3±0.2、18.1±0.2、18.9±0.2、20.2±0.2、21.0±0.2、22.7±0.2、23.8±0.2、24.0±0.2、24.9±0.2、25.0±0.2、25.2±0.2、25.8±0.2、26.4±0.2 And 26.5.+ -. 0.2.
2. Form a of bupivacaine meloxicam salt according to claim 1, characterized in that the X-ray powder diffraction pattern of form a is substantially as shown in figure 1.
3. Form a of bupivacaine meloxicam salt according to any of claims 1 to 2, characterized in that the differential scanning calorimetry curve of form a has an endothermic peak at 189.6 ℃ ± 3 ℃.
4. The crystalline form a of bupivacaine meloxicam salt according to any one of claims 1 to 2, characterized in that the thermogram of the crystalline form a has a weight loss of 57% ± 1% in the range of 210 ℃ to 300 ℃.
5. Form a of bupivacaine meloxicam salt according to any one of claims 1 to 2, characterized in that the infrared spectrum of form a comprises the following absorption peaks:
3436cm-1、3291cm-1、2960cm-1、1690cm-1、1603cm-1、1549cm-1、1522cm-1、1456cm-1、1395cm-1、1337cm-1、1233cm-1、1188cm-1、1169cm-1、1125cm-1、1067cm-1、941cm-1、861cm-1、768cm-1、741cm-1、619cm-1、574cm-1、524cm-1 And 464cm -1.
6. A process for the preparation of form a of bupivacaine meloxicam salt according to any one of claims 1 to 5, comprising the steps of:
Mixing bupivacaine, meloxicam and an organic solvent, heating and refluxing until the bupivacaine, meloxicam and the organic solvent are dissolved, concentrating the reaction solution until solid is separated out, adding an anti-solvent, continuously separating out the solid, collecting the solid, and drying to prepare an A crystal form of the bupivacaine meloxicam salt;
the organic solvent is one or more of butanone, acetone, tetrahydrofuran, acetonitrile, dimethyl sulfoxide, ethyl acetate and isopropyl acetate;
The antisolvent is one or more of water, isopropanol and n-heptane;
The volume ratio of the organic solvent to the antisolvent is 1-4:1;
the molar ratio of meloxicam to bupivacaine is 1:1-5;
the ratio between the total mass of the bupivacaine and meloxicam and the total volume of the organic solvent and the antisolvent is 7 mg-20 mg:1mL;
the temperature of heating reflux is 30-80 ℃;
The time for continuously precipitating the solid is 2-8 hours;
the temperature for continuously precipitating the solid is 0-40 ℃;
The drying temperature is 30-60 ℃.
7. The process for the preparation of form a of bupivacaine meloxicam salt according to claim 6, characterized by one of the following features:
(1) The organic solvent is acetone;
(2) The antisolvent is water;
(3) The volume ratio of the organic solvent to the antisolvent is 1.5-2.5:1;
(4) The molar ratio of meloxicam to bupivacaine is 1:1-2;
(5) The ratio between the total mass of the bupivacaine and meloxicam and the total volume of the organic solvent and the antisolvent is 7 mg-11 mg:1mL;
(6) The temperature of heating reflux is 58-62 ℃;
(7) The time for continuously precipitating the solid is 3-5 hours;
(8) The temperature for continuously precipitating the solid is 20-30 ℃;
(9) The drying temperature is 45-55 ℃;
(10) The concentration temperature is 40-50 deg.c and the pressure is-0.2 MPa to-0.1 MPa.
8. A single crystal form a of bupivacaine meloxicam salt according to any one of claims 1 to 5, characterized in that in the unit cell structure of the single crystal, one unit cell comprises 4 single crystal molecules of bupivacaine meloxicam salt.
9. The single crystal of form a of bupivacaine meloxicam salt according to claim 8, wherein the independent symmetry elements in the unit cell structure of the single crystal are double helical axis and n slip plane.
10. Single crystal of form a of bupivacaine meloxicam salt according to claim 8 or 9, characterized in that the crystallographic structural parameters of the single crystal are as follows:
11. A pharmaceutical composition comprising one or more of the crystalline form a of bupivacaine meloxicam salt according to any one of claims 1 to 5 and the single crystal of crystalline form a of bupivacaine meloxicam salt according to any one of claims 8 to 10, together with a pharmaceutically acceptable carrier and/or excipient.
12. Use of a crystalline form a of bupivacaine meloxicam salt according to any one of claims 1 to 5, a single crystal of a crystalline form a of bupivacaine meloxicam salt according to any one of claims 8 to 10 or a pharmaceutical composition according to claim 11 for the preparation of a medicament having an effect of treating localized pain.
CN202211281061.0A 2022-10-19 2022-10-19 Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof Active CN115894340B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211281061.0A CN115894340B (en) 2022-10-19 2022-10-19 Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof
PCT/CN2023/120714 WO2024082917A1 (en) 2022-10-19 2023-09-22 Crystal form a of bupivacaine-meloxicam salt, single crystal thereof, preparation method therefor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211281061.0A CN115894340B (en) 2022-10-19 2022-10-19 Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN115894340A CN115894340A (en) 2023-04-04
CN115894340B true CN115894340B (en) 2024-07-16

Family

ID=86487422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211281061.0A Active CN115894340B (en) 2022-10-19 2022-10-19 Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof

Country Status (2)

Country Link
CN (1) CN115894340B (en)
WO (1) WO2024082917A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894340B (en) * 2022-10-19 2024-07-16 加立(深圳)生物科技有限公司 Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof
CN118090983B (en) * 2024-04-26 2024-09-06 山东齐都药业有限公司 Method for detecting active substances in bupivacaine/meloxicam recovery prescription gel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110117250A (en) * 2018-02-06 2019-08-13 四川科伦药物研究院有限公司 A kind of preparation method of Bupivacaine crystal form
CN113827547A (en) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 Sustained-release preparation composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007030695A1 (en) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-crystal, useful e.g. to prepare a pharmaceutical formulation for the treatment of psychosis, neurological disorder and struma lymphomatosa, comprises an amino compound and urea as further component
EP2244712B1 (en) * 2008-01-22 2015-08-05 Thar Pharmaceuticals Inc. In vivo studies of crystalline forms of meloxicam
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN113614077A (en) * 2018-11-05 2021-11-05 迈兰实验室有限公司 Meloxicam cocrystal
CN111747947A (en) * 2020-07-30 2020-10-09 山东第一医科大学(山东省医学科学院) Meloxicam-urea eutectic crystal and preparation method thereof
CN115894340B (en) * 2022-10-19 2024-07-16 加立(深圳)生物科技有限公司 Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof
CN116041342B (en) * 2022-12-30 2024-02-20 加立(深圳)生物科技有限公司 Crystal form I of ropivacaine/meloxicam salt monohydrate, pharmaceutical composition, preparation method and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110117250A (en) * 2018-02-06 2019-08-13 四川科伦药物研究院有限公司 A kind of preparation method of Bupivacaine crystal form
CN113827547A (en) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 Sustained-release preparation composition

Also Published As

Publication number Publication date
WO2024082917A1 (en) 2024-04-25
CN115894340A (en) 2023-04-04

Similar Documents

Publication Publication Date Title
CN115894340B (en) Crystal form A of bupivacaine meloxicam salt and single crystal, preparation method and application thereof
TWI588145B (en) Noribogaine salt ansolvates
CN116041342B (en) Crystal form I of ropivacaine/meloxicam salt monohydrate, pharmaceutical composition, preparation method and application thereof
CN110494423B (en) Novel crystal form of lenvatinib mesylate and preparation method thereof
CN110088088B (en) Novel crystal form of { [5- (3-chlorphenyl) -3-hydroxypyridine-2-carbonyl ] amino } acetic acid and preparation method thereof
WO2022121670A1 (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
AU2017336889B2 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
WO2017107972A1 (en) Novel crystalline form of selective s1p1 receptor agonist and method for preparing same
CN102351857A (en) Tropiseiron hydrochloride compound
CN110799501B (en) Crystal form of orexin receptor antagonist and preparation method and application thereof
US20170210760A1 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
US20200181121A1 (en) Cocrystal of Telmisartan and Hydrochlorothiazide
CN110078780B (en) Preparation method and application of progesterone eutectic
JP2020500912A (en) Crystal Form of Bromodomain Protein Inhibitor, Production Method and Use Thereof
CN110944982A (en) Crystal form of ozapimod hydrochloride and preparation method thereof
CN112770756A (en) Udacetitinib crystal form and preparation method and application thereof
CN109400598B (en) Eutectic crystal of berberine hydrochloride and lactic acid, preparation method and application thereof
JP4566128B2 (en) Method for producing crystalline polymorph of irinotecan hydrochloride
WO2023193563A1 (en) Crystal form a of thienopyridine compound, and preparation method therefor and pharmaceutical composition thereof
WO2023078424A1 (en) Crystal form of kras mutant inhibitor, preparation method therefor, and use thereof
US10947185B2 (en) Crystal form of dezocine and preparation method therefor
WO2016078587A1 (en) Lu ae58054 hydrochloride crystalline form a, and preparation method and application thereof
AU2023247631A1 (en) P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof
KR101285050B1 (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
CN108948018B (en) Benzodiazepine derivatives, their salts and related crystalline forms, preparation and use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant